AGMB on Nasdaq
AgomAb Therapeutics NV
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development expenses | -48.9M EUR | -39.3M EUR | -26.3M EUR |
| General and administrative expenses | -12.8M EUR | -10.1M EUR | -6.1M EUR |
| Total operating expenses | -61.7M EUR | -49.4M EUR | -32.4M EUR |
| Other operating income | 2.4M EUR | 1.4M EUR | 1.2M EUR |
| Operating loss | -59.3M EUR | -48.0M EUR | -31.2M EUR |
| Changes in fair value of financial liabilities | -4.9M EUR | 848.0K EUR | 19.0M EUR |
| Financial expenses | -133.0K EUR | -357.0K EUR | -86.0K EUR |
| Financial income | 1.7M EUR | 1.3M EUR | 303.0K EUR |
| Loss before taxes | -62.5M EUR | -46.3M EUR | -12.0M EUR |
| Income tax (expense)/income | -4.0K EUR | 619.0K EUR | |
| Loss for the year | -62.5M EUR | -46.3M EUR | -11.4M EUR |
| Weighted average number of common shares outstanding, Basic | 541.1K shares | 541.1K shares | 541.1K shares |
| Weighted average number of common shares outstanding, Diluted | 541.1K shares | 541.1K shares | 541.1K shares |
| Basic loss per share (in ) | -143.22 EUR | -107.09 EUR | -35.63 EUR |
| Diluted loss per share (in ) | -143.22 EUR | -107.09 EUR | -35.63 EUR |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 |
|---|---|---|---|
| Intangible assets | 20.1M EUR | 20.1M EUR | |
| Goodwill | 8.6M EUR | 8.6M EUR | |
| Property, plant and equipment | 503.0K EUR | 619.0K EUR | |
| Right-of-use assets | 1.1M EUR | 1.4M EUR | |
| Other financial assets | 11.0K EUR | 12.0K EUR | |
| Other non-current assets | 2.1M EUR | 1.8M EUR | |
| Total non-current assets | 32.5M EUR | 32.5M EUR | |
| Other current assets | 4.7M EUR | 2.4M EUR | |
| Current financial investments | 30.1M EUR | ||
| Cash and cash equivalents | 86.4M EUR | 171.5M EUR | |
| Total current assets | 121.2M EUR | 173.8M EUR | |
| Total assets | 153.7M EUR | 206.4M EUR | |
| Share capital | 223.1M EUR | 223.1M EUR | 48.4M EUR |
| Share premium reserve | 76.6M EUR | 76.6M EUR | 33.7M EUR |
| Retained earnings | -181.7M EUR | -119.2M EUR | |
| Share-based payment reserves | 13.9M EUR | 8.5M EUR | |
| Other reserves | -967.0K EUR | -966.0K EUR | |
| Equity attributable to the owners of the parent | 130.9M EUR | 188.1M EUR | |
| Total equity | 130.9M EUR | 188.1M EUR | |
| Non-current lease liabilities | 1.0M EUR | 1.3M EUR | |
| Non-current contingent consideration | 3.2M EUR | 7.9M EUR | |
| Total non-current liabilities | 4.2M EUR | 9.2M EUR | |
| Current lease liabilities | 249.0K EUR | 273.0K EUR | |
| Current contingent consideration | 6.5M EUR | ||
| Trade and other payables | 10.3M EUR | 8.1M EUR | |
| Deferred income and accrued charges | 1.5M EUR | 801.0K EUR | |
| Total current liabilities | 18.6M EUR | 9.1M EUR | |
| Total liabilities | 22.8M EUR | 18.3M EUR | |
| Total equity and liabilities | 153.7M EUR | 206.4M EUR |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss for the year | -62.5M EUR | -46.3M EUR | -11.4M EUR |
| Current income tax expense (income) | 4.0K EUR | 3.0K EUR | |
| Deferred income tax expense (income) | -622.0K EUR | ||
| Fair value (gain) loss on financial assets | -96.0K EUR | ||
| Fair value (gain) loss on financial liabilities | 4.9M EUR | -848.0K EUR | -19.0M EUR |
| Depreciation & amortization | 219.0K EUR | 311.0K EUR | 99.0K EUR |
| Share-based payment expenses | 5.4M EUR | 1.1M EUR | 2.2M EUR |
| Net foreign exchange losses (gains) | 57.0K EUR | 231.0K EUR | |
| Interest expense | 69.0K EUR | 77.0K EUR | 86.0K EUR |
| Interest income | -1.6M EUR | -1.2M EUR | -303.0K EUR |
| Operating cash flows before movements in working capital | -53.7M EUR | -46.6M EUR | -28.9M EUR |
| Decrease/(increase) in other current assets | -2.3M EUR | -315.0K EUR | 1.3M EUR |
| Decrease/(increase) in other non-current assets | -363.0K EUR | -342.0K EUR | -331.0K EUR |
| Increase / (decrease) in trade and other payables. | 2.4M EUR | -230.0K EUR | 3.7M EUR |
| Increase/(decrease) in deferred income | 747.0K EUR | -395.0K EUR | -580.0K EUR |
| Income taxes paid | -4.0K EUR | -3.0K EUR | |
| Interest paid | -69.0K EUR | -10.0K EUR | -20.0K EUR |
| Interest received | 1.6M EUR | 1.1M EUR | 245.0K EUR |
| Net cash flow from /(used in) operating activities | -51.7M EUR | -46.8M EUR | -24.6M EUR |
| Purchases of property, plant and equipment | 4.0K EUR | 675.0K EUR | |
| Purchase of financial investments | -30.0M EUR | 40.0M EUR | |
| Payment of contingent consideration from previous acquisition | -3.0M EUR | ||
| Net cash flow from /(used in) investing activities | -33.0M EUR | -675.0K EUR | 40.0M EUR |
| Repayment of lease liabilities | -338.0K EUR | -163.0K EUR | -100.0K EUR |
| Proceeds from capital increase | 97.1M EUR | 79.9M EUR | |
| Share issue costs | -129.0K EUR | -453.0K EUR | |
| Other financial expense, net | 6.0K EUR | ||
| Net cash flow from /(used in) financing activities | -338.0K EUR | 96.8M EUR | 79.3M EUR |
| Net increase/(decrease) in cash and cash equivalents | -85.1M EUR | 49.3M EUR | 94.7M EUR |
| Effect of foreign exchange rate changes | 45.0K EUR | -204.0K EUR |
Recent filings
- Oct 13, 20266-K
- Oct 9, 20264 PRIMARY DOCUMENT
- Oct 7, 20264 PRIMARY DOCUMENT
- Oct 7, 20264 PRIMARY DOCUMENT
- Oct 7, 20264 PRIMARY DOCUMENT
- Oct 1, 20266-K
- Sep 15, 20263 OWNERSHIP DOCUMENT
- Sep 15, 20263 OWNERSHIP DOCUMENT
- Sep 15, 20264 OWNERSHIP DOCUMENT
- Sep 15, 20264 OWNERSHIP DOCUMENT
- Sep 14, 20266-K
- Sep 11, 20266-K
- Aug 10, 20266-K
- Aug 6, 20266-K
- Jun 23, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3